Amendments to the Claims:

1. (currently amended) An antigen composition capable of eliciting an enhanced cytotoxic T cell response in the context of a major histocompatibility complex class I molecule (MHC class I), comprising an antigen having an added peptidic sequence comprising one or more sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, wherein said added peptidic sequence [which] facilitates entry of said antigen into antigen presenting cells (APC).

2. (original) The antigen composition of claim 1, wherein said added peptidic sequence comprises one or more sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7.

3. (withdrawn) The antigen composition of claim 1, wherein said added peptidic sequence comprises a sequence presented as CYS- $[X\text{-}Y\text{-}Y\text{-}Y\text{-}Y\text{-}Y]_n$; wherein X= glu or asp, Y = ala, leu, ile, phe, gly, cys, met or val and n is greater than or equal to 3 or $[X\text{-}Y\text{-}Y\text{-}Y\text{-}Y\text{-}Y]_n$; wherein X= glu or asp, Y = ala, leu, ile, phe, gly, cys, met or val and n is greater than or equal to 3.

4. (currently amended) The antigen composition of claim [2] 1, wherein said antigen is a soluble protein antigen.

5. (currently amended) The antigen composition of claim 4 for use in immunizing a subject against a tumor or pathogen where said [antigen] antigen is specific to the tumor or pathogen.

6. (currently amended) The antigen composition of claim [2] 1, wherein said one or more added peptidic sequences are covalently linked to said antigen.

7. (currently amended) The antigen composition of claim [2] 1 wherein said antigen is a fusion protein produced by translation of a continuous nucleotide coding sequence.